

Previously published in the U.S. Credit Alpha  
8 November 2019

## Tracking Global CLO Ownership

### US Credit Strategy

Alin Florea  
+1 212 412 2123  
alin.florea@barclays.com  
BCI, US

### European Credit Strategy

Geoffrey Horton, CFA  
+44 (0) 20 3134 2680  
geoffrey.horton@barclays.com  
Barclays, UK

Previously published in European Credit Alpha, November 8, 2019.

While we understand the increased scrutiny of structured products, as the CLO market grows to new highs and takes up a larger share of the loan market, along with increasing ownership of loans by CLOs (*CLOs Take More of the Demand Pie*, November 1, 2019), the recent global regulatory focus has shown us that the pool of CLO holders is not as opaque as once thought. Reports by the Fed, Bank of England, Bank of Japan, and others have shown that we can trace CLO holder exposure for a large majority of the CLO market, with this transparency only set to increase in the future.


### Global CLO Market Now Approximately \$770bn

We estimate that the global CLO market is now approximately \$770bn in size, up 19% year-to-date and 63% since the start of 2016. As the AAA tranche typically comprises most of a CLO's liability structure, the balance of AAA tranches outstanding is c.\$455bn, or 59% of total CLO outstanding. Our estimates for the remainder of the liability stack include: AAs at 11%, single-As at 7%, BBBs at 6%, BBs at 5%, single-Bs at 1%, and equity at 12%.

US CLOs, at c.\$650bn, are the largest portion of the global CLO market. US broadly syndicated loan (BSL) CLOs represent \$593bn of the total, with the remainder from middle market (MM) CLOs (c.\$55bn). The US CLO market has grown more than 17% year-to-date and 59% since YE2015 (Figure 1). While the BSL market dominates the MM segment in size, growth in MM CLOs has been strong, near 150% since YE2015, increasing share from 5.4% to 8.4%.


The European CLO market is much smaller in comparison, at €109bn, or roughly \$120bn. While smaller, the European CLO market has grown more quickly than the US market this year, at 25% year-to-date and 88% since the start of 2016 (Figure 2). Unlike the US, though, the European CLO market did not begin to grow materially until later in 2016, when post-crisis issuance began to outpace pre-crisis deal paydowns.

FIGURE 1  
The US CLO Market Has Grown More Than 17% This Year



Source: Kanerai, Intex, Barclays Research

FIGURE 2  
The European CLO Market Has Grown More, at 25% Year-to-Date




Source: Kanerai, Intex, Barclays Research

## **Holders of CLO Tranches Continue to Emerge**

Despite the increased transparency of the global CLO holder base, it is still difficult to pinpoint exact CLO tranche exposure. Therefore, similar to our analysis for the rest of US securitized products in *Duration in Demand*, November 1, 2019, we provide rough estimates for global CLO ownership based on a variety of recent regulatory reports, industry publications, and filings (Figure 3).

FIGURE 3  
Global CLO Tranche Ownership Estimated Breakdown



Source: BOE, BOJ, FED, FDIC, Lipper, HFR, NAIC, Fitch, Bloomberg, company financials, Barclays Research

**Banks (33-36%):** Banks across the globe continue to be the largest holders of CLO tranches, with a vast majority of their holdings concentrated in AAA tranches.

We estimate that Japanese, US, and European banks hold 32-34% of global CLOs outstanding, with another 1-2% possibly held by banking intuitions outside these regions. In combination, we estimate that banking institutions make up nearly 60% of the global CLO AAA market.

- Japanese banks:** Despite the decline in Japanese bank participation in the global CLO market this year, we estimate that Japanese banks still hold roughly 15% of the global CLO tranches outstanding. Even after the Japanese Financial Services Agency's implementation of a risk retention solution (where investors, for example, have to prove the underlying assets were properly originated), we believe Japanese banks will continue to be a major investor in the asset class, albeit buying at a slower pace, as the opportunity set of higher yielding, highly rated global assets declines.
- US banks:** We estimate that US-domiciled banks hold just under \$100bn in CLO tranches, or roughly 12-13% of the global CLO market and 15-18% of the US CLO market. Although total US bank holdings have increased slightly y/y, they have not kept pace with the growth in the outstanding CLO market, leading to a slight decrease in US CLO market share terms relative to last year (-1 percentage point).
- European banks:** We estimate that European banks hold roughly 5% of global CLO tranches, weighted primarily to European CLOs. We think that European banks have increased their purchasing this year, replacing some of the reduced buying from Japanese banks, as AAA CLO tranches remain attractive compared with other credit and structured products, even on a risk-weighted basis, as discussed in *European CLO AAA Relative Value Update*, October 18, 2019.

**Insurers (23-25%):** US and European insurance companies are the second largest buyer-type of CLO tranches. We estimate that another 1-2% is held by other regional insurers. For example, Bloomberg recently reported that Korean insurers hold just under \$3bn in estimated CLO exposure.

- **US insurers:** Most of the global insurer exposure to CLOs is weighted to US insurers, specifically life insurers, holding roughly 17-18% of the global CLO market and 19-21% of the US CLO market. We estimate that US insurers have increased their market share of US CLOs by 5 percentage points y/y based on the NAIC's most recent Schedule D filings.

We believe this was largely driven by the prevalence of CLO combo notes, where insurers are major investors, as well as the old NAIC rules that allowed notching of NAIC designations based on purchase price (see [Where Breakpoints Break Down](#), March 29, 2019). Given that the rules went into effect in March 2019, before the effective date of the new rules that no longer allow a more favorable treatment for bonds purchased below par, we think the rate of future purchases could slow.

Nonetheless, this slowdown could be offset in part by the continued prevalence of combo notes, which may continue to be issued given the NAIC 2 designation they currently receive, despite packaging equity exposure that would otherwise be mapped to a NAIC 6 designation. The ability to use external ratings for CLO combo notes could change soon, though, as the Securities Valuation Office is reconsidering its methodology for NAIC designations of principal protected notes. A move away from using rating agency ratings to using a look-through approach to create a new NAIC designation may change the attractive relative value perspective of CLO combo notes for US insurers.

CLO tranche rating exposure for US insurers differs, but is concentrated primarily in investment grade-rated tranches (AAA through single-A). As of the end of 2018, the NAIC noted that US insurer exposure to AAA CLO tranches was 43%, with 81% exposure to BBB or higher rated tranches. There was some equity exposure as well, though we believe it to be held in combo notes.

- **European insurers:** In contrast to US insurers, European insurers incur higher capital charges holding for CLO tranches under the Solvency II regime. As a result, European insurer exposure to the global CLO market is lower at approximately 4%, but is still meaningful in terms of the European CLO market. Similar to US insurers, though, most of the underlying CLO tranche rating exposure is concentrated in IG-rated tranches.

**Asset managers/mutual funds/SMAs (12-15%):** We estimate that asset managers, mutual funds, and separately managed accounts (SMAs), which invest across the entire CLO ratings stack, hold roughly 12-15% of the global CLO tranches outstanding.

We think that asset managers have decreased their exposure to CLOs this year given lower rates in the US, decreasing yields for CLO tranches, pressure from investor outflows as CLOs continue to underperform, and continued uncertainty about EU Securitization Regulations, which has affected EU and US managers with UCITS vehicles alike.

UCITS exposure to CLOs was approximately €36bn at the end of 2018, and AIFs likely exceed €20bn, pushing the total that is subject to the new rules well over €50bn. We believe this may decrease next year, depending on the ability of the managers to comply with the new loan-level templates and clarification on whether the rules apply to non-EU deals. Should the EUSR apply to non-EU deals, we do not necessarily anticipate a reduction in CLO demand from the end investors but, instead, a reallocation of CLOs away from UCITS and into US-domiciled vehicles, such as US-based mutual funds or SMAs.

**Pension funds (10-13%):** Similarly, we believe that pension funds, which tend to focus more on IG-rated tranches, have slightly pared exposure to the CLO market this year, as lower rates have made floating rates less attractive for these investors. In addition, continued negative headlines about the asset class are likely keeping structured credit allocations from increasing materially.

**Hedge funds/CLO managers (8-12%):** Hedge fund and CLO manager exposure to CLOs, which is primarily focused on BB, single-B, and equity tranches, is more difficult to estimate, but from conversations with market participants, we believe these investors have overall maintained exposure to the asset class this year.

The decline in CLO mezz and equity prices this year has likely pushed returns lower for structured credit funds with CLO exposure and may have driven a slowdown or even reversal of inflows. However, funds with more locked-up capital could increase their exposure to CLOs in the near future, given the attractive value of CLO mezz and equity relative to other credit in both the US and Europe recently (Figure 4) and the growing number of positive convexity opportunities, as discussed in our *Global CLO Update*, October 31, 2019.

As the CLO equity arb has also remained challenged this year, we believe more CLO managers have raised dedicated equity retention funds, or simply retained more CLO equity on new deals relative to past years, increasing their market share of CLO equity. We expect this trend to continue.

**Other/unknown (5-10%):** The remaining CLO tranche holders are even more difficult to pinpoint. While some of this range could be attributed to the rough estimations reported for the other CLO holder types and may shrink in the future as regulatory agency reporting standards become even more precise, we believe some of these unknown holders may be based in regions of the world that are generally not accounted for in broader industry reports (eg, outside Japan, the US, and Europe) or do not have standardized reporting methods for CLO exposure yet.

FIGURE 4  
Global CLO Mezz Continues to Widen Relative to Other Credit



Source: S&P LCD, Intex, Barclays Research. Note: CLO spreads are generic primary levels. Loan spreads 3y DM.

**Analyst Certification**

We, Alin Florea and Geoffrey Horton, CFA, hereby certify (1) that the views expressed in this research report accurately reflect our personal views about any or all of the subject securities or issuers referred to in this research report and (2) no part of our compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed in this research report.

**Important Disclosures:**

Barclays Research is produced by the Investment Bank of Barclays Bank PLC and its affiliates (collectively and each individually, "Barclays").

All authors contributing to this research report are Research Analysts unless otherwise indicated. The publication date at the top of the report reflects the local time where the report was produced and may differ from the release date provided in GMT.

**Availability of Disclosures:**

For current important disclosures regarding any issuers which are the subject of this research report please refer to <https://publicresearch.barclays.com> or alternatively send a written request to: Barclays Research Compliance, 745 Seventh Avenue, 13th Floor, New York, NY 10019 or call +1-212-526-1072.

Barclays Capital Inc. and/or one of its affiliates does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that Barclays may have a conflict of interest that could affect the objectivity of this report. Barclays Capital Inc. and/or one of its affiliates regularly trades, generally deals as principal and generally provides liquidity (as market maker or otherwise) in the debt securities that are the subject of this research report (and related derivatives thereof). Barclays trading desks may have either a long and / or short position in such securities, other financial instruments and / or derivatives, which may pose a conflict with the interests of investing customers. Where permitted and subject to appropriate information barrier restrictions, Barclays fixed income research analysts regularly interact with its trading desk personnel regarding current market conditions and prices. Barclays fixed income research analysts receive compensation based on various factors including, but not limited to, the quality of their work, the overall performance of the firm (including the profitability of the Investment Banking Department), the profitability and revenues of the Markets business and the potential interest of the firm's investing clients in research with respect to the asset class covered by the analyst. To the extent that any historical pricing information was obtained from Barclays trading desks, the firm makes no representation that it is accurate or complete. All levels, prices and spreads are historical and do not necessarily represent current market levels, prices or spreads, some or all of which may have changed since the publication of this document. Barclays Research Department produces various types of research including, but not limited to, fundamental analysis, equity-linked analysis, quantitative analysis, and trade ideas. Recommendations and trade ideas contained in one type of Barclays Research may differ from those contained in other types of Barclays Research, whether as a result of differing time horizons, methodologies, or otherwise.

In order to access Barclays Statement regarding Research Dissemination Policies and Procedures, please refer to <https://publicresearch.barcap.com/S/RD.htm>. In order to access Barclays Research Conflict Management Policy Statement, please refer to: <https://publicresearch.barcap.com/S/CM.htm>.

All pricing information is indicative only. Unless otherwise indicated, prices are sourced from Refinitiv and reflect the closing price in the relevant trading market, which may not be the last available price at the time of publication.

**Types of investment recommendations produced by Barclays FICC Research:**

In addition to any ratings assigned under Barclays' formal rating systems, this publication may contain investment recommendations in the form of trade ideas, thematic screens, scorecards or portfolio recommendations that have been produced by analysts in FICC Research. Any such investment recommendations produced by non-Credit Research teams shall remain open until they are subsequently amended, rebalanced or closed in a future research report. Any such investment recommendations produced by the Credit Research teams are valid at current market conditions and may not be otherwise relied upon.

**Disclosure of other investment recommendations produced by Barclays FICC Research:**

Barclays FICC Research may have published other investment recommendations in respect of the same securities/instruments recommended in this research report during the preceding 12 months. To view all investment recommendations published by Barclays FICC Research in the preceding 12 months please refer to <https://live.barcap.com/go/research/Recommendations>.

**Legal entities involved in producing Barclays Research:**

Barclays Bank PLC (Barclays, UK)  
Barclays Capital Inc. (BCI, US)  
Barclays Bank Ireland PLC, Frankfurt Branch (BBI, Frankfurt)  
Barclays Bank Ireland PLC, Paris Branch (BBI, Paris)  
Barclays Bank Ireland PLC, Milan Branch (BBI, Milan)  
Barclays Securities Japan Limited (BSJL, Japan)  
Barclays Bank PLC, Hong Kong branch (Barclays Bank, Hong Kong)  
Barclays Capital Canada Inc. (BCCI, Canada)  
Barclays Bank Mexico, S.A. (BBMX, Mexico)  
Barclays Securities (India) Private Limited (BSIPL, India)  
Barclays Bank PLC, India branch (Barclays Bank, India)  
Barclays Bank PLC, Singapore branch (Barclays Bank, Singapore)  
Barclays Bank PLC, DIFC Branch (Barclays Bank, DIFC)

**Disclaimer**

This publication has been produced by Barclays Research Department in the Investment Bank of Barclays Bank PLC and/or one or more of its affiliates (collectively and each individually, "Barclays"). It has been prepared for institutional investors and not for retail investors. It has been distributed by one or more Barclays affiliated legal entities listed below. It is provided to our clients for information purposes only, and Barclays makes no express or implied

warranties, and expressly disclaims all warranties of merchantability or fitness for a particular purpose or use with respect to any data included in this publication. To the extent that this publication states on the front page that it is intended for institutional investors and is not subject to all of the independence and disclosure standards applicable to debt research reports prepared for retail investors under U.S. FINRA Rule 2242, it is an "institutional debt research report" and distribution to retail investors is strictly prohibited. Barclays also distributes such institutional debt research reports to various issuers, media, regulatory and academic organisations for their own internal informational news gathering, regulatory or academic purposes and not for the purpose of making investment decisions regarding any debt securities. Media organisations are prohibited from re-publishing any opinion or recommendation concerning a debt issuer or debt security contained in any Barclays institutional debt research report. Any such recipients that do not want to continue receiving Barclays institutional debt research reports should contact [debtresearch@barclays.com](mailto:debtresearch@barclays.com). Clients that are subscribed to receive equity research reports, will not receive certain cross asset research reports co-authored by equity and FICC research analysts that are distributed as "institutional debt research reports" unless they have agreed to accept such reports. Eligible clients may get access to such cross asset reports by contacting [debtresearch@barclays.com](mailto:debtresearch@barclays.com). Barclays will not treat unauthorized recipients of this report as its clients and accepts no liability for use by them of the contents which may not be suitable for their personal use. Prices shown are indicative and Barclays is not offering to buy or sell or soliciting offers to buy or sell any financial instrument.

Without limiting any of the foregoing and to the extent permitted by law, in no event shall Barclays, nor any affiliate, nor any of their respective officers, directors, partners, or employees have any liability for (a) any special, punitive, indirect, or consequential damages; or (b) any lost profits, lost revenue, loss of anticipated savings or loss of opportunity or other financial loss, even if notified of the possibility of such damages, arising from any use of this publication or its contents.

Other than disclosures relating to Barclays, the information contained in this publication has been obtained from sources that Barclays Research believes to be reliable, but Barclays does not represent or warrant that it is accurate or complete. Barclays is not responsible for, and makes no warranties whatsoever as to, the information or opinions contained in any written, electronic, audio or video presentations of third parties that are accessible via a direct hyperlink in this publication or via a hyperlink to a third-party web site ('Third-Party Content'). Any such Third-Party Content has not been adopted or endorsed by Barclays, does not represent the views or opinions of Barclays, and is not incorporated by reference into this publication. Third-Party Content is provided for information purposes only and Barclays has not independently verified its accuracy or completeness.

The views in this publication are solely and exclusively those of the authoring analyst(s) and are subject to change, and Barclays Research has no obligation to update its opinions or the information in this publication. Unless otherwise disclosed herein, the analysts who authored this report have not received any compensation from the subject companies in the past 12 months. If this publication contains recommendations, they are general recommendations that were prepared independently of any other interests, including those of Barclays and/or its affiliates, and/or the subject companies. This publication does not contain personal investment recommendations or investment advice or take into account the individual financial circumstances or investment objectives of the clients who receive it. The securities and other investments discussed herein may not be suitable for all investors. Barclays is not a fiduciary to any recipient of this publication. Investors must independently evaluate the merits and risks of the investments discussed herein, consult any independent advisors they believe necessary, and exercise independent judgment with regard to any investment decision. The value of and income from any investment may fluctuate from day to day as a result of changes in relevant economic markets (including changes in market liquidity). The information herein is not intended to predict actual results, which may differ substantially from those reflected. Past performance is not necessarily indicative of future results. The information provided does not constitute a financial benchmark and should not be used as a submission or contribution of input data for the purposes of determining a financial benchmark.

**United Kingdom:** This document is being distributed (1) only by or with the approval of an authorised person (Barclays Bank PLC) or (2) to, and is directed at (a) persons in the United Kingdom having professional experience in matters relating to investments and who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"); or (b) high net worth companies, unincorporated associations and partnerships and trustees of high value trusts as described in Article 49(2) of the Order; or (c) other persons to whom it may otherwise lawfully be communicated (all such persons being "Relevant Persons"). Any investment or investment activity to which this communication relates is only available to and will only be engaged in with Relevant Persons. Any other persons who receive this communication should not rely on or act upon it. Barclays Bank PLC is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority and is a member of the London Stock Exchange.

**European Economic Area ("EEA"):** This material is being distributed in the EEA by Barclays Bank PLC. Barclays Bank PLC is not registered in France with the Autorité des marchés financiers or the Autorité de contrôle prudentiel.

**Americas:** The Investment Bank of Barclays Bank PLC undertakes U.S. securities business in the name of its wholly owned subsidiary Barclays Capital Inc., a FINRA and SIPC member. Barclays Capital Inc., a U.S. registered broker/dealer, is distributing this material in the United States and, in connection therewith, accepts responsibility for its contents. Any U.S. person wishing to effect a transaction in any security discussed herein should do so only by contacting a representative of Barclays Capital Inc. in the U.S. at 745 Seventh Avenue, New York, New York 10019.

Non-U.S. persons should contact and execute transactions through a Barclays Bank PLC branch or affiliate in their home jurisdiction unless local regulations permit otherwise.

This material is distributed in Canada by Barclays Capital Canada Inc., a registered investment dealer, a Dealer Member of IIROC ([www.iiroc.ca](http://www.iiroc.ca)), and a Member of the Canadian Investor Protection Fund (CIPF).

This material is distributed in Mexico by Barclays Bank Mexico, S.A.

**Japan:** This material is being distributed to institutional investors in Japan by Barclays Securities Japan Limited. Barclays Securities Japan Limited is a joint-stock company incorporated in Japan with registered office of 6-10-1 Roppongi, Minato-ku, Tokyo 106-6131, Japan. It is a subsidiary of Barclays Bank PLC and a registered financial instruments firm regulated by the Financial Services Agency of Japan. Registered Number: Kanto Zaimukyokucho (kinsho) No. 143.

**Asia Pacific (excluding Japan):** Barclays Bank PLC, Hong Kong Branch is distributing this material in Hong Kong as an authorised institution regulated by the Hong Kong Monetary Authority. Registered Office: 41/F, Cheung Kong Center, 2 Queen's Road Central, Hong Kong.

All Indian securities-related research and other equity research produced by Barclays' Investment Bank are distributed in India by Barclays Securities (India) Private Limited (BSIPL). BSIPL is a company incorporated under the Companies Act, 1956 having CIN U67120MH2006PTC161063. BSIPL is registered and regulated by the Securities and Exchange Board of India (SEBI) as a Research Analyst: INH000001519; Portfolio Manager INP000002585; Stock Broker/Trading and Clearing Member: National Stock Exchange of India Limited (NSE) Capital Market INB231292732, NSE Futures & Options INF231292732, NSE Currency derivatives INE231450334, Bombay Stock Exchange Limited (BSE) Capital Market INB011292738, BSE Futures & Options INF011292738; Depository Participant (DP) with the National Securities & Depositories Limited (NSDL): DP ID: IN-DP-NSDL-299-2008; Investment Adviser: INA000000391. The registered office of BSIPL is at 208, Ceejay House, Shivasagar Estate, Dr. A. Besant Road, Worli, Mumbai – 400 018, India. Telephone No: +91 2267196000.

Fax number: +91 22 67196100. Any other reports produced by Barclays' Investment Bank are distributed in India by Barclays Bank PLC, India Branch, an associate of BSIPL in India that is registered with Reserve Bank of India (RBI) as a Banking Company under the provisions of The Banking Regulation Act, 1949 (Regn No BOM43) and registered with SEBI as Merchant Banker (Regn No INM000002129) and also as Banker to the Issue (Regn No INBI00000950). Barclays Investments and Loans (India) Limited, registered with RBI as Non Banking Financial Company (Regn No RBI CoR-07-00258), and Barclays Wealth Trustees (India) Private Limited, registered with Registrar of Companies (CIN U93000MH2008PTC188438), are associates of BSIPL in India that are not authorised to distribute any reports produced by Barclays' Investment Bank.

This material is distributed in Singapore by the Singapore branch of Barclays Bank PLC, a bank licensed in Singapore by the Monetary Authority of Singapore. For matters in connection with this material, recipients in Singapore may contact the Singapore branch of Barclays Bank PLC, whose registered address is 10 Marina Boulevard, #23-01 Marina Bay Financial Centre Tower 2, Singapore 018983.

This material is distributed to persons in Australia by Barclays Bank PLC. None of Barclays Bank PLC, nor any other Barclays group entity, holds an Australian financial services licence and instead relies on an exemption from the requirement to hold such a licence. This material is intended to only be distributed to "wholesale clients" as defined by the Australian Corporations Act 2001.

**Middle East:** Nothing herein should be considered investment advice as defined in the Israeli Regulation of Investment Advisory, Investment Marketing and Portfolio Management Law, 1995 ("Advisory Law"). This document is being made to eligible clients (as defined under the Advisory Law) only. Barclays Israeli branch previously held an investment marketing license with the Israel Securities Authority but it cancelled such license on 30/11/2014 as it solely provides its services to eligible clients pursuant to available exemptions under the Advisory Law, therefore a license with the Israel Securities Authority is not required. Accordingly, Barclays does not maintain an insurance coverage pursuant to the Advisory Law.

This material is distributed in the United Arab Emirates (including the Dubai International Financial Centre) and Qatar by Barclays Bank PLC. Barclays Bank PLC in the Dubai International Financial Centre (Registered No. 0060) is regulated by the Dubai Financial Services Authority (DFSA). Principal place of business in the Dubai International Financial Centre: The Gate Village, Building 4, Level 4, PO Box 506504, Dubai, United Arab Emirates. Barclays Bank PLC-DIFC Branch, may only undertake the financial services activities that fall within the scope of its existing DFSA licence. Related financial products or services are only available to Professional Clients, as defined by the Dubai Financial Services Authority. Barclays Bank PLC in the UAE is regulated by the Central Bank of the UAE and is licensed to conduct business activities as a branch of a commercial bank incorporated outside the UAE in Dubai (Licence No.: 13/1844/2008, Registered Office: Building No. 6, Burj Dubai Business Hub, Sheikh Zayed Road, Dubai City) and Abu Dhabi (Licence No.: 13/952/2008, Registered Office: Al Jazira Towers, Hamdan Street, PO Box 2734, Abu Dhabi). Barclays Bank PLC in the Qatar Financial Centre (Registered No. 00018) is authorised by the Qatar Financial Centre Regulatory Authority (QFCRA). Barclays Bank PLC-QFC Branch may only undertake the regulated activities that fall within the scope of its existing QFCRA licence. Principal place of business in Qatar: Qatar Financial Centre, Office 1002, 10th Floor, QFC Tower, Diplomatic Area, West Bay, PO Box 15891, Doha, Qatar. Related financial products or services are only available to Business Customers as defined by the Qatar Financial Centre Regulatory Authority.

**Russia:** This material is not intended for investors who are not Qualified Investors according to the laws of the Russian Federation as it might contain information about or description of the features of financial instruments not admitted for public offering and/or circulation in the Russian Federation and thus not eligible for non-Qualified Investors. If you are not a Qualified Investor according to the laws of the Russian Federation, please dispose of any copy of this material in your possession.

**IRS Circular 230 Prepared Materials Disclaimer:** Barclays does not provide tax advice and nothing contained herein should be construed to be tax advice. Please be advised that any discussion of U.S. tax matters contained herein (including any attachments) (i) is not intended or written to be used, and cannot be used, by you for the purpose of avoiding U.S. tax-related penalties; and (ii) was written to support the promotion or marketing of the transactions or other matters addressed herein. Accordingly, you should seek advice based on your particular circumstances from an independent tax advisor.

© Copyright Barclays Bank PLC (2019). All rights reserved. No part of this publication may be reproduced or redistributed in any manner without the prior written permission of Barclays. Barclays Bank PLC is registered in England No. 1026167. Registered office 1 Churchill Place, London, E14 5HP. Additional information regarding this publication will be furnished upon request.

BRCF2242

